BACKGROUND. Few studies have evaluated the late effects of adjuvant chemotherapy for breast cancer. Moreover, the relation between the risk of leukemia and the amount of drug given and the interaction of chemotherapy with radiotherapy have not been described in detail. METHODS. We conducted a case-control study in a cohort of 82,700 women given a diagnosis of breast cancer from 1973 to 1985 in five areas of the United States. Detailed information about therapy was obtained for 90 patients with leukemia and 264 matched controls. The dose of radiation to the active marrow was estimated from individual radiotherapy records (mean dose, 7.5 Gy). RESULTS. The risk of acute nonlymphocytic leukemia was significantly increased after regional radiotherapy alone (relative risk, 2.4), alkylating agents alone (relative risk, 10.0), and combined radiation and drug therapy (relative risk, 17.4). Dose-dependent risks were observed after radiotherapy and treatment with melphalan and cyclophosphamide. Melphalan was 10 times more leukemogenic than cyclophosphamide (relative risk, 31.4 vs. 3.1). There was little increase in the risk associated with total cyclophosphamide doses of less than 20,000 mg. CONCLUSIONS. Although leukemia occurs in few patients with breast cancer, significantly elevated risks were linked to treatments with regional radiation and alkylating agents. Melphalan is a more potent leukemogen than cyclophosphamide or radiotherapy. Low risks were associated with the levels of cyclophosphamide in common use today. Systemic drug therapy combined with radiotherapy that delivers high doses to the marrow appears to enhance the risk of leukemia.
Source Information
Radiation Epidemiology Branch, National Cancer Institute, Bethesda, Md. 20892.
This article has been cited by other articles:
Eriguchi, M., Oka, H., Mizobuchi, T., Kamimura, T., Sugawara, K., Harada, A.
(2009). Long-term outcomes of idiopathic membranous nephropathy in Japanese patients treated with low-dose cyclophosphamide and prednisolone. Nephrol Dial Transplant
24: 3082-3088
[Abstract][Full Text]
Chakraborty, S., Sun, C.-L., Francisco, L., Sabado, M., Li, L., Chang, K. L., Forman, S., Bhatia, S., Bhatia, R.
(2009). Accelerated Telomere Shortening Precedes Development of Therapy-Related Myelodysplasia or Acute Myelogenous Leukemia After Autologous Transplantation for Lymphoma. JCO
27: 791-798
[Abstract][Full Text]
Beadle, G., Baade, P., Fritschi, L.
(2009). Acute myeloid leukemia after breast cancer: a population-based comparison with hematological malignancies and other cancers. Ann Oncol
20: 103-109
[Abstract][Full Text]
Ono, M., Watanabe, T., Shimizu, C., Hiramoto, N., Goto, Y., Yonemori, K., Kouno, T., Ando, M., Tamura, K., Katsumata, N., Fujiwara, Y.
(2008). Therapy-Related Acute Promyelocytic Leukemia Caused by Hormonal Therapy and Radiation in a Patient with Recurrent Breast Cancer. Jpn J Clin Oncol
38: 567-570
[Abstract][Full Text]
Schaapveld, M., Visser, O., Louwman, M. J., de Vries, E. G.E., Willemse, P. H.B., Otter, R., van der Graaf, W. T.A., Coebergh, J.-W. W., van Leeuwen, F. E.
(2008). Risk of New Primary Nonbreast Cancers After Breast Cancer Treatment: A Dutch Population-Based Study. JCO
26: 1239-1246
[Abstract][Full Text]
Bernatsky, S, Joseph, L, Boivin, J-F, Gordon, C, Urowitz, M, Gladman, D, Fortin, P R, Ginzler, E, Bae, S-C, Barr, S, Edworthy, S, Isenberg, D, Rahman, A, Petri, M, Alarcon, G S, Aranow, C, Dooley, M-A, Rajan, R, Senecal, J-L, Zummer, M, Manzi, S, Ramsey-Goldman, R, Clarke, A E
(2008). The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. Ann Rheum Dis
67: 74-79
[Abstract][Full Text]
Bastianutto, C., Mian, A., Symes, J., Mocanu, J., Alajez, N., Sleep, G., Shi, W., Keating, A., Crump, M., Gospodarowicz, M., Medin, J., Minden, M., Liu, F.-F.
(2007). Local Radiotherapy Induces Homing of Hematopoietic Stem Cells to the Irradiated Bone Marrow. Cancer Res.
67: 10112-10116
[Abstract][Full Text]
Patt, D. A., Duan, Z., Fang, S., Hortobagyi, G. N., Giordano, S. H.
(2007). Acute Myeloid Leukemia After Adjuvant Breast Cancer Therapy in Older Women: Understanding Risk. JCO
25: 3871-3876
[Abstract][Full Text]
Le Deley, M.-C., Suzan, F., Cutuli, B., Delaloge, S., Shamsaldin, A., Linassier, C., Clisant, S., de Vathaire, F., Fenaux, P., Hill, C.
(2007). Anthracyclines, Mitoxantrone, Radiotherapy, and Granulocyte Colony-Stimulating Factor: Risk Factors for Leukemia and Myelodysplastic Syndrome After Breast Cancer. JCO
25: 292-300
[Abstract][Full Text]
Travis, L. B.
(2007). Evaluation of the Risk of Therapy-Associated Complications in Survivors of Hodgkin Lymphoma. ASH Education Book
2007: 192-196
[Abstract][Full Text]
Travis, L. B.
(2006). The Epidemiology of Second Primary Cancers. Cancer Epidemiol. Biomarkers Prev.
15: 2020-2026
[Abstract][Full Text]
Fenske, T. S., McMahon, C., Edwin, D., Jarvis, J. C., Cheverud, J. M., Minn, M., Mathews, V., Bogue, M. A., Province, M. A., McLeod, H. L., Graubert, T. A.
(2006). Identification of candidate alkylator-induced cancer susceptibility genes by whole genome scanning in mice.. Cancer Res.
66: 5029-5038
[Abstract][Full Text]
Young, S. D., Whissell, M., Noble, J. C.S., Cano, P. O., Lopez, P. G., Germond, C. J.
(2006). Phase II Clinical Trial Results Involving Treatment with Low-Dose Daily Oral Cyclophosphamide, Weekly Vinblastine, and Rofecoxib in Patients with Advanced Solid Tumors.. Clin. Cancer Res.
12: 3092-3098
[Abstract][Full Text]
d'Errico, F.
(2006). Dosimetric issues in radiation protection of radiotherapy patients. Radiat Prot Dosimetry
118: 205-212
[Abstract][Full Text]
Davis, S, International Consortium For Research On The Healt, , Day, R., Kopecky, K., Mahoney, M., McCarthy, P., Michalek, A., Moysich, K., Onstad, L., Stepanenko, V., Voilleque, P., Other members of Study Team:, , Chegerova, T, Falkner, K, Kulikov, S, Maslova, E, Ostapenko, V, Rivkind, N, Shevchuk, V, Tsyb, A.
(2006). Childhood leukaemia in Belarus, Russia, and Ukraine following the Chernobyl power station accident: results from an international collaborative population-based case-control study. Int J Epidemiol
35: 386-396
[Abstract][Full Text]
Travis, L. B., Rabkin, C. S., Brown, L. M., Allan, J. M., Alter, B. P., Ambrosone, C. B., Begg, C. B., Caporaso, N., Chanock, S., DeMichele, A., Figg, W. D., Gospodarowicz, M. K., Hall, E. J., Hisada, M., Inskip, P., Kleinerman, R., Little, J. B., Malkin, D., Ng, A. K., Offit, K., Pui, C.-H., Robison, L. L., Rothman, N., Shields, P. G., Strong, L., Taniguchi, T., Tucker, M. A., Greene, M. H.
(2006). Cancer Survivorship--Genetic Susceptibility and Second Primary Cancers: Research Strategies and Recommendations. JNCI J Natl Cancer Inst
98: 15-25
[Abstract][Full Text]
Shin, S. J., Chun, S. H., Kim, K. O., Kim, M. K., Lee, K. H., Hyun, M. S., Cho, H. S.
(2005). Myelodysplastic Syndrome with Complex Karyotypic Abnormality in a Patient with Waldenstrom's Macroglobulinemia after Sequential Treatment with Chlorambucil and Fludarabine. Jpn J Clin Oncol
35: 622-625
[Abstract][Full Text]
Campone, M., Roche, H., Kerbrat, P., Bonneterre, J., Romestaing, P., Fargeot, P., Namer, M., Monnier, A., Montcuquet, P., Goudier, M.-J., Fumoleau, P., On behalf of the FASG (French Adjuvant Study Group,
(2005). Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group. Ann Oncol
16: 1343-1351
[Abstract][Full Text]
Praga, C., Bergh, J., Bliss, J., Bonneterre, J., Cesana, B., Coombes, R. C., Fargeot, P., Folin, A., Fumoleau, P., Giuliani, R., Kerbrat, P., Hery, M., Nilsson, J., Onida, F., Piccart, M., Shepherd, L., Therasse, P., Wils, J., Rogers, D.
(2005). Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Trials of Adjuvant Epirubicin for Early Breast Cancer: Correlation With Doses of Epirubicin and Cyclophosphamide. JCO
23: 4179-4191
[Abstract][Full Text]
Wefel, J. S., Meyers, C. A.
(2005). Cancer as a Risk Factor for Dementia: A House Built on Shifting Sand. JNCI J Natl Cancer Inst
97: 788-789
[Full Text]
Pruneri, G., Cinieri, S., Peccatori, F., Viale, G.
(2005). Unusual Cases in Multiple Myeloma and a Dramatic Response in Metastatic Lung Cancer: CASE 2. Plasma Cell Myeloma Coexisting With Metastatic Breast Carcinoma in the Bone Marrow. JCO
23: 232-233
[Full Text]
Truong, P. T., Olivotto, I. A., Whelan, T. J., Levine, M.
(2004). Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy. CMAJ
170: 1263-1273
[Abstract][Full Text]
Andre, M., Mounier, N., Leleu, X., Sonet, A., Brice, P., Henry-Amar, M., Tilly, H., Coiffier, B., Bosly, A., Morel, P., Haioun, C., Gaulard, P., Reyes, F., Gisselbrecht, C., the Groupe d'Etude des Lymphomes de l'Adulte,
(2004). Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood
103: 1222-1228
[Abstract][Full Text]
Crump, M., Tu, D., Shepherd, L., Levine, M., Bramwell, V., Pritchard, K.
(2003). Risk of Acute Leukemia Following Epirubicin-Based Adjuvant Chemotherapy: A Report From the National Cancer Institute of Canada Clinical Trials Group. JCO
21: 3066-3071
[Abstract][Full Text]
Beaumont, M., Sanz, M., Carli, P.M., Maloisel, F., Thomas, X., Detourmignies, L., Guerci, A., Gratecos, N., Rayon, C., San Miguel, J., Odriozola, J., Cahn, J.Y., Huguet, F., Vekhof, A., Stamatoulas, A., Dombret, H., Capote, F., Esteve, J., Stoppa, A.M., Fenaux, P.
(2003). Therapy-Related Acute Promyelocytic Leukemia. JCO
21: 2123-2137
[Abstract][Full Text]
Arriagada, R., Gutierrez, J.
(2003). Anthracyclines: is more, better and/or more dangerous?. Ann Oncol
14: 663-665
[Full Text]
Bernard-Marty, C., Mano, M., Paesmans, M., Accettura, C., Munoz-Bermeo, R., Richard, T., Kleiber, K., Cardoso, F., Lobelle, J. P., Larsimont, D., Piccart, M. J., Di Leo, A.
(2003). Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients. Ann Oncol
14: 693-698
[Abstract][Full Text]
Rauscher, G. H., Sandler, D. P., Poole, C., Pankow, J., Shore, D., Bloomfield, C. D., Olshan, A. F.
(2003). Is Family History of Breast Cancer a Marker of Susceptibility to Exposures in the Incidence of de Novo Adult Acute Leukemia?. Cancer Epidemiol. Biomarkers Prev.
12: 289-294
[Abstract][Full Text]
Kroger, N., Zander, A. R., Martinelli, G., Ferrante, P., Moraleda, J. M., Da Prada, G. A., Demirer, T., Socie, G., Rosti, G.
(2003). Low incidence of secondary myelodysplasia and acute myeloid leukemia after high-dose chemotherapy as adjuvant therapy for breast cancer patients: a study by the Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation. Ann Oncol
14: 554-558
[Abstract][Full Text]
Smith, R. E., Bryant, J., DeCillis, A., Anderson, S.
(2003). Acute Myeloid Leukemia and Myelodysplastic Syndrome After Doxorubicin-Cyclophosphamide Adjuvant Therapy for Operable Breast Cancer: The National Surgical Adjuvant Breast and Bowel Project Experience. JCO
21: 1195-1204
[Abstract][Full Text]
Metayer, C., Curtis, R. E., Vose, J., Sobocinski, K. A., Horowitz, M. M., Bhatia, S., Fay, J. W., Freytes, C. O., Goldstein, S. C., Herzig, R. H., Keating, A., Miller, C. B., Nevill, T. J., Pecora, A. L., Rizzo, J. D., Williams, S. F., Li, C.-Y., Travis, L. B., Weisdorf, D. J.
(2003). Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood
101: 2015-2023
[Abstract][Full Text]
Ghalie, R G, Mauch, E, Edan, G, Hartung, H P, Gonsette, R E, Eisenmann, S, Le Page, E, Butine, M D, Goodkin, D E
(2002). A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler
8: 441-445
[Abstract]
Colleoni, M., Rocca, A., Sandri, M. T., Zorzino, L., Masci, G., Nole, F., Peruzzotti, G., Robertson, C., Orlando, L., Cinieri, S., Braud, F. d., Viale, G., Goldhirsch, A.
(2002). Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol
13: 73-80
[Abstract][Full Text]
National Institutes of Health Consensus Developmen,
(2001). National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000. J Natl Cancer Inst Monogr
2001: 5-15
[Abstract][Full Text]
Partridge, A. H., Burstein, H. J., Winer, E. P.
(2001). Side Effects of Chemotherapy and Combined Chemohormonal Therapy in Women With Early-Stage Breast Cancer. J Natl Cancer Inst Monogr
2001: 135-142
[Abstract][Full Text]
(2001). National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000. JNCI J Natl Cancer Inst
93: 979-989
[Abstract][Full Text]
Shapiro, C. L., Recht, A.
(2001). Side Effects of Adjuvant Treatment of Breast Cancer. NEJM
344: 1997-2008
[Full Text]
van Besien, K., Kelta, M., Bahaguna, P.
(2001). Primary Mediastinal B-Cell Lymphoma: A Review of Pathology and Management. JCO
19: 1855-1864
[Abstract][Full Text]
Recht, A., Edge, S. B., Solin, L. J., Robinson, D. S., Estabrook, A., Fine, R. E., Fleming, G. F., Formenti, S., Hudis, C., Kirshner, J. J., Krause, D. A., Kuske, R. R., Langer, A. S., Sledge, G. W. Jr, Whelan, T. J., Pfister, D. G.
(2001). Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology. JCO
19: 1539-1569
[Abstract][Full Text]
Chaplain, G., Milan, C., Sgro, C., Carli, P.-M., Bonithon-Kopp, C.
(2000). Increased Risk of Acute Leukemia After Adjuvant Chemotherapy for Breast Cancer: A Population-Based Study. JCO
18: 2836-2842
[Abstract][Full Text]
Travis, L. B., Andersson, M., Gospodarowicz, M., van Leeuwen, F. E., Bergfeldt, K., Lynch, C. F., Curtis, R. E., Kohler, B. A., Wiklund, T., Storm, H., Holowaty, E., Hall, P., Pukkala, E., Sleijfer, D. T., Clarke, E. A., Boice, J. D. Jr., Stovall, M., Gilbert, E.
(2000). Treatment-Associated Leukemia Following Testicular Cancer. JNCI J Natl Cancer Inst
92: 1165-1171
[Abstract][Full Text]
Benson, K., Hartz, A. J.
(2000). A Comparison of Observational Studies and Randomized, Controlled Trials. NEJM
342: 1878-1886
[Abstract][Full Text]
Whelan, T. J., Julian, J., Wright, J., Jadad, A. R., Levine, M. L.
(2000). Does Locoregional Radiation Therapy Improve Survival in Breast Cancer? A Meta-Analysis. JCO
18: 1220-1229
[Abstract][Full Text]
Krishnan, A., Bhatia, S., Slovak, M. L., Arber, D. A., Niland, J. C., Nademanee, A., Fung, H., Bhatia, R., Kashyap, A., Molina, A., O'Donnell, M. R., Parker, P. A., Sniecinski, I., Snyder, D. S., Spielberger, R., Stein, A., Forman, S. J.
(2000). Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood
95: 1588-1593
[Abstract][Full Text]
Travis, L. B., Holowaty, E. J., Bergfeldt, K., Lynch, C. F., Kohler, B. A., Wiklund, T., Curtis, R. E., Hall, P., Andersson, M., Pukkala, E., Sturgeon, J., Stovall, M., Storm, H., Clarke, E. A., Boice, J. D., Gospodarowicz, M.
(1999). Risk of Leukemia after Platinum-Based Chemotherapy for Ovarian Cancer. NEJM
340: 351-357
[Abstract][Full Text]
Smith, M. A., Rubinstein, L., Anderson, J. R., Arthur, D., Catalano, P. J., Freidlin, B., Heyn, R., Khayat, A., Krailo, M., Land, V. J., Miser, J., Shuster, J., Vena, D.
(1999). Secondary Leukemia or Myelodysplastic Syndrome After Treatment With Epipodophyllotoxins. JCO
17: 569-569
[Abstract][Full Text]
Riemer, G., Lamszus, K., Zschaber, R., Freitag, H. J., Eggers, C., Pfeiffer, G.
(1999). Isolated angiitis of the central nervous system: Lack of inflammation after long-term treatment. Neurology
52: 196-196
[Abstract][Full Text]
de Lima, M., Strom, S. S., Keating, M., Kantarjian, H., Pierce, S., O'Brien, S., Freireich, E., Estey, E.
(1997). Implications of Potential Cure in Acute Myelogenous Leukemia: Development of Subsequent Cancer and Return to Work. Blood
90: 4719-4724
[Abstract][Full Text]
(1992). RISK OF LEUKEMIA AFTER TREATMENT FOR BREAST CANCER. JWatch General
1992: 1-1
[Full Text]
Previous
